Brief: Rain Oncology Reports Fourth Quarter And Full Year 2022 Financial Results

Rain Oncology

09/03/2023 21:09

March 9 (Reuters) - Rain Oncology Inc  RAIN.O :
    * RAIN ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2022
FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS
    * PHASE 1/2 MANTRA-4 TRIAL ANTICIPATED TO COMMENCE IN
MID-2023
    * TOPLINE DATA FOR PHASE 3 PIVOTAL MANTRA TRIAL EXPECTED IN
Q2 OF
2023
    * PHASE 2 MANTRA-2 TRIAL CONTINUES TO ENROLL
    * QTRLY LOSS PER SHARE $0.70
    * AS OF DECEMBER 31, 2022, RAIN HAD $130.5 MILLION IN CASH,
CASH
EQUIVALENTS AND SHORT-TERM INVESTMENTS.
    * RAIN WILL NOT PROVIDE GUIDANCE ON CASH RUNWAY AT THIS TIME
    * Q4 EARNINGS PER SHARE VIEW $-0.56 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX4NwTYt 
Further company coverage:  RAIN.O 

 ((Reuters.Briefs@thomsonreuters.com;))